Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement (Q34570640)

3 August 2017

1 reference

title

Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement (English)

1 reference

3 August 2017

Monsinjon T

1

1 reference

3 August 2017

Richard V

series ordinal

2

1 reference

3 August 2017

Fontaine M

series ordinal

3

1 reference

3 August 2017

publication date

1 October 2001

1 reference

Fundamental and Clinical Pharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

15

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

293-306

1 reference

The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Complement localization and mediation of ischemic injury in baboon myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Reduction by Cobra Venom Factor of Myocardial Necrosis after Coronary Artery Occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Long-Term Preservation of Ischemic Myocardium after Experimental Coronary Artery Occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Reoxygenation of Hypoxic Human Umbilical Vein Endothelial Cells Activates the Classic Complement Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Membrane signaling by complement C5b-9, the membrane attack complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Complement activation after oxidative stress: role of the lectin complement pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Neutrophil accumulation in ischemic canine myocardium. Insights into time course, distribution, and mechanism of localization during early reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

C5a-induced expression of P-selectin in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Role of complement, chemokines, and regulatory cytokines in acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Complement inhibitors in myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Sialyl Lewisx-containing oligosaccharide attenuates myocardial reperfusion injury in cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

A novel sialyl LewisX analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

An oligosaccharide sialyl-Lewis(x) analogue does not reduce myocardial infarct size after ischemia and reperfusion in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Therapeutic uses of recombinant complement protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Expression of recombinant CD59 with an N-terminal peptide epitope facilitates analysis of residues contributing to its complement-inhibitory function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Improved right ventricular function after intracoronary administration of a C1 esterase inhibitor in a right heart transplantation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Complement-specific antibodies: Designing novel anti-inflammatories

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Preparation and characterization of monoclonal antibodies against the fifth component of rabbit complement (C5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Endothelial nuclear factor-kappaB translocation and vascular cell adhesion molecule-1 induction by complement: inhibition with anti-human C5 therapy or cGMP analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Structure-function studies in a series of carboxyl-terminal octapeptide analogs of anaphylatoxin C5a

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Pharmacological characterization of antagonists of the C5a receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Complement activation following reoxygenation of hypoxic human endothelial cells: role of intracellular reactive oxygen species, NF-kappaB and new protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Solution structure of Compstatin, a potent complement inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Effect of magnesium sulfate pretreatment and significance of matrix metalloproteinase-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

N-Acetylheparin pretreatment reduces infarct size in the rabbit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Sublytic complement attack reduces infarct size in rabbit isolated hearts: evidence for C5a-mediated cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Infectious diseases associated with complement deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Production of transgenic pigs expressing human DAF (CD55) regulated by the porcine MCP gene promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

Inhibition of Heparin/Protamine Complex-Induced Complement Activation by Compstatin in Baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00040.X

10.1046/J.1472-8206.2001.00040.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference